Four weeks SGLT2 inhibition improves beta cell function and glucose tolerance without affecting muscle free fatty acid or glucose uptake in subjects with type 2 diabetes

Jens Hohwü Voigt,Katrine M. Lauritsen,Steen Bønløkke Pedersen,Troels K. Hansen,Niels Møller,Niels Jessen,Marcello C. Laurenti,Chiara Dalla Man,Adrian Vella,Lars C. Gormsen,Esben Søndergaard
DOI: https://doi.org/10.1111/bcpt.13991
2024-02-28
Basic & Clinical Pharmacology & Toxicology
Abstract:Despite improvement in beta‐cell function and glucose tolerance, 4 weeks of empagliflozin treatment does not appear to have significant effects on skeletal muscle glucose and FFA metabolism or intra‐ and extracellular signalling pathways. Aims Sodium glucose co‐transporter‐2 (SGLT2) inhibition lowers glucose levels independently of insulin, leading to reduced insulin secretion and increased lipolysis, resulting in elevated circulating free fatty acids (FFAs). While SGLT2 inhibition improves tissue insulin sensitivity, the increase in circulating FFAs could reduce insulin sensitivity in skeletal muscle and the liver. We aimed to investigate the effects of SGLT2 inhibition on substrate utilization in skeletal muscle and the liver and to measure beta‐cell function and glucose tolerance. Methods Thirteen metformin‐treated individuals with type 2 diabetes were randomized to once‐daily empagliflozin 25 mg or placebo for 4 weeks in a crossover design. Skeletal muscle glucose and FFA uptake together with hepatic tissue FFA uptake were measured using [18F]FDG positron emission tomography/computed tomography (PET/CT) and [11C]palmitate PET/CT. Insulin secretion and action were estimated using the oral minimal model. Results Empagliflozin did not affect glucose (0.73 ± 0.30 vs. 1.16 ± 0.64, μmol/g/min p = 0.11) or FFA (0.60 ± 0.30 vs. 0.56 ± 0.3, μmol/g/min p = 0.54) uptake in skeletal muscle. FFA uptake in the liver (21.2 ± 10.1 vs. 19 ± 8.8, μmol/100 ml/min p = 0.32) was unaffected. Empagliflozin increased total beta‐cell responsivity (20 ± 8 vs. 14 ± 9, 10−9 min−1, p
pharmacology & pharmacy,toxicology
What problem does this paper attempt to address?